论文部分内容阅读
目的通过直肠癌患者在化疗前和化疗结束时的肝功能检验指标的变化以及其与HLA-DRB1、HLA-DQB1多态性的关联,以期找到直肠癌化疗副损伤的相关基因。方法选取78例直肠癌患者,采用多聚酶链反应-序列特异性引物(PCR-SSP)法检测其HLA-DRB1、HLA-DQB1的多态性。同时检测直肠癌患者化疗前和化疗结束时的肝功能检验指标,包括:TBIL、DBIL、TP、ALB、ALT、AST、ALP、GGT。结果 HLA-DRB1*07有可能是化疗对ALB、ALT损伤的抵抗基因;HLA-DRB1*08有可能是化疗对ALB、ALT损伤的抵抗基因;HLA-DRB1*09有可能是化疗对ALB、ALT损伤的抵抗基因;HLA-DRB1*12有可能是化疗对ALB、ALT损伤的抵抗基因;HLA-DQB1*02有可能是化疗对ALB、ALT损伤的抵抗基因;HLA-DQB1*05有可能是化疗对ALB损伤的抵抗基因;HLA-DQB1*06有可能是化疗对ALT损伤的抵抗基因,同时HLA-DQB1*06也可能是化疗对ALB损伤的敏感基因。结论 HLA可能是肿瘤化疗副损伤的标志性基因。
Objective To detect the changes of liver function tests and the association with HLA-DRB1 and HLA-DQB1 polymorphisms in patients with rectal cancer before chemotherapy and at the end of chemotherapy so as to find out the related genes of chemotherapy-induced side effects of rectal cancer. Methods 78 patients with rectal cancer were enrolled in this study. The polymorphisms of HLA-DRB1 and HLA-DQB1 were detected by polymerase chain reaction-sequence-specific primers (PCR-SSP). At the same time, the indexes of liver function testing before and at the end of chemotherapy in rectal cancer patients were detected, including TBIL, DBIL, TP, ALB, ALT, AST, ALP and GGT. Results HLA-DRB1 * 07 may be the resistance gene of ALT and ALT by chemotherapy. HLA-DRB1 * 08 may be the resistance gene of ALT and ALT by chemotherapy. HLA-DRB1 * HLA-DRB1 * 12 may be the resistance gene of chemotherapy against ALB and ALT; HLA-DQB1 * 02 may be the resistance gene of ALT and ALT; HLA-DQB1 * 05 may be chemotherapy HLA-DQB1 * 06 may be the resistance gene for ALT injury by chemotherapy, and HLA-DQB1 * 06 may also be the sensitive gene for the chemotherapy of ALB damage. Conclusion HLA may be a landmark gene for chemotherapy-induced side effects.